[Bone marrow aplasia related to ticlopidine].
The authors report two cases of bone marrow aplasia observed 2 months after initiation of a treatment with ticlopidine. The outcome was favorable after discontinuation of therapy. The frequency of this severe drug-induced complication seems to have been underestimated. The absolute necessity of a careful haematological survey during the first 3 months of therapy is pointed out.
de Jaureguiberry
J P
JP
Service de médecine interne-oncologie, hôpital d'instruction des Armées Sainte-Anne, Toulon, France.
Galzin
M
M
Talard
P
P
Marlier
S
S
Durupt
S
S
Bouchiat
C
C
Dussarat
G V
GV
Jaubert
D
D
D000368:Aged; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013988:Ticlopidine / Q000009:adverse effects*
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine